A5065553373- Malaria Research and Control
- Complement system in diseases
- Viral gastroenteritis research and epidemiology
- Hepatitis Viruses Studies and Epidemiology
- vaccines and immunoinformatics approaches
- Vector-borne infectious diseases
- HIV Research and Treatment
Fundação Oswaldo Cruz
2013-2014
Abstract Background Plasmodium vivax has the potential to infect 2.85 billion individuals worldwide. Nevertheless, limited number of studies investigating immune status living in malaria-endemic areas, as well lack reports serological markers associated with clinical protection, hampered development vaccines for P. . It was previously demonstrated that naturally total IgG against N-terminus merozoite surface protein 1 (Pv-MSP1) reduced risk malarial infection. Methods Immune response Pv-MSP1...
The diversity of MSP1 in both Plasmodium falciparum and P. vivax is presumed be associated to parasite immune evasion. In this study, we assessed genetic the most variable domain vaccine candidate N-terminal PvMSP1 (Block 2) field isolates Manaus. Forty-seven blood samples polymorphism Block 2 generates four fragment sizes. twenty-eight them, sequencing indicated seven haplotypes circulating among isolates. Evidence striking exchanges was observed with two stretches flanking repeat region...